64
Views
18
CrossRef citations to date
0
Altmetric
Original Article

Granulocyte colony-Stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: Effects, role of patient pretreatment characteristics, and costs

, , , , , , , , , , & show all
Pages 153-161 | Received 09 Aug 1996, Published online: 05 Aug 2009

References

  • Bassan R., Battista R., Corneo G., et al. Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. Leuk Lymph 1993; 11: 105–110
  • Bassan R., Battista R., Viero P., et al. Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. Semin Oncol 1993; 20(Suppl 8)39–46
  • Ames M. M., Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992; 6(Suppl 1)70–75
  • Minderman H., Linssen P., van der Lely N., et al. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia 1994; 8: 382–387
  • Bassan R., Lerede T., Rambaldi A., Barbui T. Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. Acta Haematol 1996; 95: 188–192
  • Weathley K. Meta-analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukaemia (Abstract). Blood 1995; (Suppl 1): 86–434a
  • Demetri G. D., Griffin J. D. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791–2808
  • Ohno R., Tomonaga M., Kobayashi T., et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871–877
  • Bennett J. M., Catovsky D., Daniel M. T., et al. Proposals for the classification of the acute leukaemias: French-american-British (FAB) Co-operative Group. Br J Haematol 1976; 33: 451–458
  • Bodey G. P., Buckley M., Sathe Y. S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–340
  • Larson R. A., Linker C. A., Dodge R. K., et al. Granulocyte-colony stimulating factor (filgrastim: G-CSF) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukemia receiving intensive remission induction chemotherapy: Cancer and Leukemia Group B study 9111 (Abstract). Proc Am Soc Clin Oncol 1994; 13: 305
  • Geissler K., Koller E., Hinterberger W., et al. Concomitant administration of granulocyte colony-stimulating factor (G-CSF) and induction chemotherapy of adult acute lymphoblastic leukemia (ALL)-First results of a multicenter, open-label, phase III study in randomized parallel groups (Abstract). Blood 1994; 81(Suppl 1)231a
  • Ottmann O. G., Hoelzer D., Gracien E., et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase IIl trial. Blood 1995; 86: 444–450
  • Scherrer R., Geissler K., Kyrle P. A., et al. Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL). Ann Hematol 1993; 66: 283–289
  • Kantarjian H. M., Estey E., O'Brien S., et al. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 1993; 72: 2950–2955
  • Tsuchiya H., Adachi N., Asou N., et al. Responses to granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF in Ph'-positive acute lymphoblastic leukemia with myeloid surface markers. Blood 1991; 77: 411–413
  • Kita K., Nishii K., Ohishi K., et al. Frequent gene expression of granulocyte colony-stimulating factor (G-CSF) receptor in CD7+ surface CD3– acute lymphoblastic leukemia. Leukemia 1993; 7: 1184–1190
  • Bassan R. The management of infections in patients with leukemia. Leukemia, E. S. Henderson, T. A. Lister, M. F. Greaves. Saunders Company, Philadelphia, W.B. 1996; 257–290
  • Sobol R. E., Mick R., Royston I., et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987; 316: 1111–1117
  • Pittaluga S., Raffeld M., Lipford E. H., Cossman J. 3A1 (CD7) expression precedes Tβ gene rearrangements in precursor T (lymphoblastic) neoplasms. Blood 1986; 66: 134–139
  • Kurtzberg J., Waldmann T. A., Davey M. P., et al. CD7+, CD4-, CD8- acute leukemia: a syndrome of malignant pluripotent lymphohematopoietic cells. Blood 1989; 73: 381–390
  • Dombret H., Chastang C., Fenaux P., et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332: 1678–1683
  • Thiel E., Rodt H., Huhn D., et al. Multimarker classification of cute lymphoblastic leukemia: evidence for further T subgroups and evaluation of their clinical significance. Blood 1980; 56: 759–772
  • Thiel E., Kranz B. R., Raghavachar A., et al. Prethymic phenotype and genotype of pre-T (CD7+/ER–)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989; 73: 1247–1258
  • Greaves M. F. Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia. Cancer Res 1981; 41: 4752–4766

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.